Loading stock data…
$18.43-0.45 (-2.38%)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Omeros Corporation in the Healthcare sector is trading at $18.59 with a market capitalization of $1.3B. Wall Street consensus targets $27.50 (2 analysts), implying a +47.9% move over the next 12 months. The stock is currently near its 52-week high of $21.24, remaining 39.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $28.53M↑ | $9.89M | $0 | $0 | $0 |
| Gross Profit | $27.73M↑ | $9.31M | — | — | $0 |
| Operating Income | $74,000↑ | -$17.42M↑ | -$29.08M↓ | -$26.39M↑ | -$32.35M |
| Net Income | $13.23M↓ | $56.06M↓ | $86.45M↑ | -$30.92M↓ | -$25.42M |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narso...